For women with PCOS, both semaglutide and tirzepatide show promise — but they work differently and access rules differ significantly in Australia.
The key difference
Ozempic is restricted for weight loss since October 2024 (diabetes only), making Mounjaro the more accessible GLP-1 option. Wegovy (same ingredient as Ozempic, higher dose) is available for weight loss.
PCOS-specific evidence
Both medications improve insulin resistance, which is a core driver of PCOS symptoms. Early studies suggest tirzepatide (Mounjaro) may have stronger effects on insulin sensitivity due to its dual mechanism. However, semaglutide (Wegovy) has more published PCOS-specific research.
Which should you choose with PCOS?
Since Ozempic is restricted for weight loss, the practical choice is between Wegovy (same ingredient as Ozempic, approved for weight loss) and Mounjaro. Both improve insulin resistance — a core driver of PCOS — alongside producing weight loss.
Mounjaro's dual GLP-1/GIP mechanism may provide stronger insulin sensitisation, though head-to-head PCOS data is limited. The higher average weight loss (~21% vs ~15-17%) is also relevant because PCOS symptoms improve proportionally with weight lost.
What about metformin?
Metformin is commonly prescribed for PCOS insulin resistance. It can generally be continued alongside GLP-1 medications — in fact, the combination may produce better outcomes than either alone. However, both metformin and GLP-1 medications cause GI side effects, so your doctor may start one at a time to identify which causes any issues.
Fertility considerations
Weight loss with PCOS significantly improves fertility markers. However, weight loss medication must be stopped at least 2 months before trying to conceive. If pregnancy is a near-term goal, discuss timing carefully with your reproductive specialist.